Search results
FDA Tells Vaccine Makers to Target New COVID Variant for Fall
WFMZ Eastern Pennsylvania and Western New Jersey· 1 day agoCOVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot...
Scientists use gene technology to develop possible antidote to black widow spider bite
UPI· 3 days agoUsing gene technology, researchers generated dozens of human antibodies that could neutralize alpha-latrotoxin, the venom generated by a black widow spider. A potential human-specific antidote ...
Scientists Find Possible Antidote to Black Widow Spider Bite
Star City News· 3 days agoA potential human-specific antidote to black widow spider venom has been discovered, researchers report. This antibody, or ones like it, could eventually replace the horse-derived ...
WHO releases report on state of development of antibacterials
World Health Organization· 22 hours agoThe World Health Organization (WHO) today released its latest report on antibacterial agents,...
EXCLUSIVE: ImmunoPrecise Antibodies' Subsidiary Releases Software With Customizable Interface For...
Benzinga· 5 days agoOn Monday, ImmunoPrecise Antibodies Ltd IPA announced that its subsidiary, BioStrand, has released the commercial version of LENSai API software. This advanced AI-driven software solution is ...
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Zacks via Yahoo Finance· 21 hours agoProthena Corp., AC Immune and Cassava Sciences are also developing therapies for Alzheimer's...
AbbVie inks deal to develop new IBD therapy with FutureGen By Investing.com
Investing.com· 2 days agoFG-M701, which is currently in the preclinical development stage, is designed as a fully human...
Santa Ana Bio secures $168m for inflammatory disease treatments
Pharmaceutical Technology via Yahoo Finance· 1 day agoAnother candidate, SAB03, is expected to enter Phase I trials in 2025 for several severe...
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
Yahoo Finance· 5 days agoAn FDA panel voted 11-0 Monday to recommend the use of Eli Lilly's (LLY) early-stage Alzheimer's...
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
The Mammoth Times· 2 days agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ...